Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: A double-blind, randomized, placebo-controlled study

Pediatric Allergy and Immunology

Volumn 17, Issue 6, 2006, Pages 408-415

  Lue, Ko Huang ^a,b   Lin, Yung Hsiang ^a   Sun, Hai Lun ^a,b   Lu, Ko Hsiu ^b   Hsieh, Jie Cheng ^a   Chou, Ming Chih ^b  

^a CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Asthma; House dust mite; IgG4; Sublingual immunotherapy

Indexed keywords

ALLERGEN; ANTIHISTAMINIC AGENT; BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CORTICOSTEROID; DERMATOPHAGOIDES FARINAE EXTRACT; EOSINOPHIL CATIONIC PROTEIN; HOUSE DUST ALLERGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; PLACEBO; PREDNISOLONE; STALORAL; TERBUTALINE; UNCLASSIFIED DRUG;

ARTICLE; ASTHMA; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; EOSINOPHIL COUNT; EVALUATION; FEMALE; FORCED EXPIRATORY VOLUME; HOUSE DUST ALLERGY; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MALE; NIGHT; PEAK EXPIRATORY FLOW; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SENSITIZATION; SKIN SENSITIVITY; SUBLINGUAL IMMUNOTHERAPY; SYMPTOM; TAIWAN;

ADMINISTRATION, SUBLINGUAL; ALLERGENS; ANTIGENS, DERMATOPHAGOIDES; ASTHMA; CHILD; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; DESENSITIZATION, IMMUNOLOGIC; DOUBLE-BLIND METHOD; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHILS; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; PEAK EXPIRATORY FLOW RATE; SKIN TESTS;

EID: 33747888983     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/j.1399-3038.2006.00443.x     Document Type: Article

References (23)

1. BOUSQUET J, LOCKEY R, MALLING HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 1998: 102(4 Pt 1): 558-62.
2. MALLING HJ, BREU-NOGUEIRA J, VAREZ-CUESTA E, et al. EAACI/ESPACI local immunotherapy position paper. Allergy 1998: 53: 933-44.
3. NELSON HS, OPPENHEIMER J, VATSIA GA, BUCHMEIER A. A double-blind, placebo-controlled evaluation of sublingual immunotherapy with standardized cat extract. J Allergy Clin Immunol 1993: 92: 229-36.
4. FELIZIANI V, LATTUADA G, PARMIANI S, DALL'AGLIO PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol Immunopathol (Madr) 1995: 23: 224-30.
5. TROISE C, VOLTOLINI S, CANESSA A, PECORA S, NEGRINI AC. Sublingual immunotherapy in Parietaria pollen-induced rhinitis: a double-blind study. J Investig Allergol Clin Immunol 1995: 5: 25-30.
6. TARI MG, MANCINO M, MONTI G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double-blind study. Allergol Immunopathol (Madr) 1990: 18: 277-84.
7. SABBAH A, HASSOUN S, LE SJ, ANDRE C, SICARD H. A double-blind, placebo-controlled trial by the sublingual route of immunotherapy with a standardized grass pollen extract. Allergy 1994: 49: 309-13.
8. PAJNO GB, MORABITO L, BARBERIO G, PARMIANI S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000: 55: 842-9.
9. HIRSCH T, SAHN M, LEUPOLD W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997: 8: 21-7.
10. BOUSQUET J, SCHEINMANN P, GUINNEPAIN MT, et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999: 54: 249-60.
11. BAHCECILER NN, ISIK U, BARLAN IB, BASARAN MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001: 32: 49-55.
12. MARCUCCI F, SENSI L, FRATI F, et al. Effects on inflammation parameters of a double-blind, placebo controlled one-year course of SLIT in children mono-sensitized to mites. Allergy 2003: 58: 657-62.
13. BODTGER U, POULSEN LK, JACOBI HH, MALLING HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002: 57: 297-305.
14. BODTGER U, JACOBSEN CR, POULSEN LK, MALLING HJ. Long-term repeatability of the skin prick test is high when supported by history or allergen-sensitivity tests: a prospective clinical study. Allergy 2003: 58: 1180-6.
15. BAHCECILER NN, ARIKAN C, TAYLOR A, et al. Impact of sublingual immunotherapy on specific antibody levels in asthmatic children allergic to house dust mites. Int Arch Allergy Immunol 2005: 136: 287-94.
16. DJURUP R. The subclass nature and clinical significance of the IgG antibody response in patients undergoing allergen-specific immunotherapy. Allergy 1985: 40: 469-86.
17. LIN KL, WANG SY, HSIEH KH. Analysis of house dust mite-specific IgE, IgG4, and IgG antibodies during immunotherapy in asthmatic children. Ann Allergy 1991: 67: 63-9.
18. LU FM, CHOU CC, CHIANG BL, HSIEH KH. Immunologic changes during immunotherapy in asthmatic children: increased IL-13 and allergen-specific IgG4 antibody levels. Ann Allergy Asthma Immunol 1998: 80: 419-23.
19. MCHUGH SM, LAVELLE B, KEMENY DM, PATEL S, EWAN PW. A placebo-controlled trial of immunotherapy with two extracts of Dermatophagoides pteronyssinus in allergic rhinitis, comparing clinical outcome with changes in antigen-specific IgE, IgG, and IgG subclasses. J Allergy Clin Immunol 1990: 86(4 Pt 1): 521-31.
20. MARCUCCI F, SENSI L, FRATI F, et al. Sublingual tryptase and ECP in children treated with grass pollen sublingual immunotherapy (SLIT): safety and immunologic implications. Allergy 2001: 56: 1091-5.
21. PASSALACQUA G, ALBANO M, FREGONESE L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998: 351: 629-32.
22. MADONINI E, AGOSTINI F, BARRA R, et al. Safety and efficacy evaluation of sublingual allergen-specific immunotherapy a retrospective, multicenter study. Int J Immunopathol Pharmacol 2000: 13: 77-81.
23. PAJNO GB, PERONI DG, VITA D, PIETROBELLI A, PARMIANI S, BONER AL. Safety of sublingual immunotherapy in children with asthma. Paediatr Drugs 2003: 5: 777-81.